The methylation status of the ADAM17 promoter was markedly higher in BRCA, KIRC, KIRP, LUSC, PAAD, PRAD, SARC, and SKCM tumor tissues than in paired normal tissues (Figure 1F–M). Here, ADAM17 is linked to prostate adenocarcinoma.